SBIO Holdings — ALPS Medical Breakthroughs ETF
All 88 reported holdings of ALPS Medical Breakthroughs ETF (SBIO) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Alkermes Plc | 4.48% | $7.24M |
| Kymera Therapeutics Inc | 4.23% | $6.85M |
| Celcuity Inc | 3.92% | $6.34M |
| Mirum Pharmaceuticals Inc | 3.90% | $6.31M |
| Spyre Therapeutics Inc | 3.68% | $5.95M |
| Cg Oncology Inc | 3.35% | $5.42M |
| Apogee Therapeutics Inc | 2.93% | $4.74M |
| Xenon Pharmaceuticals Inc | 2.90% | $4.69M |
| Travere Therapeutics Inc | 2.77% | $4.48M |
| Dianthus Therapeutics Inc | 2.64% | $4.26M |
| Newamsterdam Pharma Co Nv | 2.47% | $3.99M |
| Viking Therapeutics Inc | 2.41% | $3.90M |
| Crinetics Pharmaceuticals Inc | 2.37% | $3.84M |
| Acadia Pharmaceuticals Inc | 2.35% | $3.81M |
| Edgewise Therapeutics Inc | 2.33% | $3.78M |
| Denali Therapeutics Inc | 2.13% | $3.44M |
| Oruka Therapeutics Inc | 1.80% | $2.92M |
| Structure Therapeutics Inc | 1.78% | $2.87M |
| Disc Medicine Inc | 1.69% | $2.74M |
| Ideaya Biosciences Inc | 1.65% | $2.67M |
| Vera Therapeutics Inc | 1.61% | $2.61M |
| Tarsus Pharmaceuticals Inc | 1.61% | $2.61M |
| Relay Therapeutics Inc | 1.60% | $2.59M |
| Mineralys Therapeutics Inc | 1.59% | $2.57M |
| Celldex Therapeutics Inc | 1.33% | $2.16M |
| Zai Lab Ltd | 1.26% | $2.03M |
| Pharvaris Nv | 1.23% | $1.99M |
| Sionna Therapeutics Inc | 1.23% | $1.99M |
| Rapport Therapeutics Inc | 1.20% | $1.95M |
| Sarepta Therapeutics Inc | 1.20% | $1.93M |
| Lakefront Biotherapeutics Nv | 1.19% | $1.93M |
| Tyra Biosciences Inc | 1.15% | $1.85M |
| Novavax Inc | 1.14% | $1.84M |
| Stoke Therapeutics Inc | 1.12% | $1.82M |
| Agios Pharmaceuticals Inc | 1.10% | $1.78M |
| Vericel Corp | 1.08% | $1.74M |
| Nuvation Bio Inc | 1.06% | $1.71M |
| Palvella Therapeutics Inc | 1.03% | $1.67M |
| Taysha Gene Therapies Inc | 1.02% | $1.66M |
| Amylyx Pharmaceuticals Inc | 1.01% | $1.63M |
| Immatics Nv | 0.98% | $1.59M |
| Immunocore Holdings Plc | 0.93% | $1.51M |
| Mbx Biosciences Inc | 0.90% | $1.46M |
| Bicara Therapeutics Inc | 0.88% | $1.42M |
| Moonlake Immunotherapeutics | 0.88% | $1.42M |
| Kalvista Pharmaceuticals Inc | 0.87% | $1.40M |
| Arrivent Biopharma Inc | 0.85% | $1.38M |
| Oculis Holding Ag | 0.84% | $1.35M |
| Maze Therapeutics Inc | 0.81% | $1.31M |
| Mannkind Corp | 0.74% | $1.20M |
| Corvus Pharmaceuticals Inc | 0.66% | $1.07M |
| Olema Pharmaceuticals Inc | 0.66% | $1.07M |
| Zenas Biopharma Inc | 0.63% | $1.02M |
| Kura Oncology Inc | 0.57% | $928.71K |
| Ars Pharmaceuticals Inc | 0.57% | $928.33K |
| Xencor Inc | 0.56% | $898.09K |
| Theravance Biopharma Inc | 0.52% | $838.81K |
| Geron Corp | 0.51% | $825.31K |
| Design Therapeutics Inc | 0.41% | $666.19K |
| Alto Neuroscience Inc | 0.40% | $642.74K |
| Candel Therapeutics Inc | 0.39% | $626.65K |
| Tectonic Therapeutic Inc | 0.37% | $603.14K |
| Fulgent Genetics Inc | 0.36% | $583.94K |
| Rigel Pharmaceuticals Inc | 0.36% | $580.59K |
| Aclaris Therapeutics Inc | 0.35% | $565.58K |
| Upstream Bio Inc | 0.29% | $465.64K |
| Neurogene Inc | 0.28% | $452.53K |
| Compass Therapeutics Inc | 0.27% | $441.81K |
| Altimmune Inc | 0.25% | $408.93K |
| Vanda Pharmaceuticals Inc | 0.24% | $392.97K |
| Delcath Systems Inc | 0.24% | $386.07K |
| Atea Pharmaceuticals Inc | 0.24% | $383.52K |
| Zura Bio Ltd | 0.24% | $382.18K |
| Regenxbio Inc | 0.23% | $372.93K |
| Rezolute Inc | 0.20% | $325.52K |
| Anavex Life Sciences Corp | 0.18% | $289.43K |
| Akebia Therapeutics Inc | 0.17% | $281.64K |
| Protara Therapeutics Inc | 0.16% | $259.23K |
| Forte Biosciences Inc | 0.15% | $246.23K |
| Bicycle Therapeutics Plc | 0.15% | $241.30K |
| Arcturus Therapeutics Holdings Inc | 0.14% | $231.97K |
| Aardvark Therapeutics Inc | 0.06% | $92.22K |
| State Street Institutional Treasury Plus Money Market Fund | 0.00% | $6.74K |
| Omniab Inc | 0.00% | $0 |
| Chinook Therapeutics Inc | 0.00% | $0 |
| Astrazeneca Plc | 0.00% | $0 |
| Omniab Inc | 0.00% | $0 |
| Novo Nordisk A/s | 0.00% | $0 |
SBIO overview: performance, fees, allocation and SEC filings